RxDoctor Payments Data

Kurt Heil, MD

Family Medicine · Pittsburgh, PANPI 1316911951

Payments from drug & device makers

$1,233in general payments, 2019–2025

Across 58 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$243
  • Novo Nordisk$165
  • Pfizer$135
  • Abbott$134
  • Lilly USA, LLC$117
  • Kowa Pharmaceuticals America, Inc.$67
  • plus $371 from 13 others

What the payments were for

  • Food & beverage$1,18696%
  • Gifts$474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,233 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$190,176
Medicare patients
459
Services billed
8,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$137,177
XareltoRivaroxaban114$104,085
OzempicSemaglutide36$43,836
XifaxanRifaximin25$40,673
JardianceEmpagliflozin19$23,158
JanuviaSitagliptin Phosphate12$12,929
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,519
Atorvastatin Calcium638$7,886
SynjardyEmpagliflozin/Metformin Hcl11$6,179
Breo ElliptaFluticasone/Vilanterol15$6,079
Metoprolol Succinate284$5,850
Cyclosporine12$4,811
PaxlovidNirmatrelvir/Ritonavir18$4,288
Simvastatin367$4,271
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$135$141,465183 claims
Johnson & JohnsonXarelto$18$104,085114 claims
Novo NordiskOzempic$165$43,83636 claims
Boehringer IngelheimJardiance, Synjardy$44$29,33730 claims
GSKAnoro Ellipta, Breo Ellipta$19$14,59829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →